URGN UroGen Pharma Ltd

Price (delayed)

$27.54

Market cap

$1.34B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.74

Enterprise value

$1.43B

?
Relative Growth: Rel. Growth: 80
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 26

Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, ...

Highlights
The gross profit has surged by 53% year-on-year and by 30% since the previous quarter
The revenue has soared by 53% YoY and by 28% from the previous quarter
The quick ratio has contracted by 25% YoY but it has grown by 16% from the previous quarter
UroGen Pharma's equity has plunged by 167% YoY and by 18% from the previous quarter
URGN's debt has surged by 56% year-on-year and by 52% since the previous quarter

Key stats

What are the main financial stats of URGN

URGN stock price

How has the UroGen Pharma stock price performed over time
Intraday
3.53%
1 week
-4.01%
1 month
18.25%
1 year
459.76%
YTD
17.59%
QTD
53.17%

Financial performance

How have UroGen Pharma's revenue and profit performed over time
Revenue
$140.49M
Gross profit
$126.24M
Operating income
-$108.21M
Net income
-$133.23M
Gross margin
89.9%
Net margin
-94.8%
The gross profit has surged by 53% year-on-year and by 30% since the previous quarter
The revenue has soared by 53% YoY and by 28% from the previous quarter
URGN's net margin is up by 37% year-on-year and by 32% since the previous quarter
The operating margin is up by 34% year-on-year and by 32% since the previous quarter

Price vs fundamentals

How does URGN's price correlate with its fundamentals

Growth

What is UroGen Pharma's growth rate over time

Valuation

What is UroGen Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
9.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.15
The company's EPS rose by 14% QoQ and by 10% YoY
UroGen Pharma's equity has plunged by 167% YoY and by 18% from the previous quarter
The price to sales (P/S) is 58% higher than the 5-year quarterly average of 6.0 and 13% higher than the last 4 quarters average of 8.4
The revenue has soared by 53% YoY and by 28% from the previous quarter

Efficiency

How efficient is UroGen Pharma business performance
The company's return on sales rose by 34% YoY and by 31% QoQ
The ROA has decreased by 27% YoY but it has increased by 14% from the previous quarter
URGN's return on invested capital is up by 18% since the previous quarter

Dividends

What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for URGN.

Financial health

How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 33% lower than its total liabilities
The total liabilities is up by 29% year-on-year and by 24% since the previous quarter
UroGen Pharma's total assets has increased by 27% QoQ and by 2.5% YoY
UroGen Pharma's equity has plunged by 167% YoY and by 18% from the previous quarter
URGN's debt has surged by 56% year-on-year and by 52% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.